Chinook Therapeutics to Present at Upcoming Investor Conferences
Chinook Therapeutics (NASDAQ: KDNY) recently announced upcoming fireside chats at key investor conferences. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is set for September 22 at 11:35 AM EDT, followed by the 2021 Cantor Virtual Global Healthcare Conference on September 28 at 2:40 PM EDT. Chinook will also engage in 1x1 meetings during these events. Investors can access live webcasts and recordings on Chinook's website for 90 days. The company specializes in developing precision medicines for kidney diseases, with lead programs targeting severe chronic kidney disorders.
- None.
- None.
SEATTLE, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences:
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – live fireside chat on Wednesday, September 22nd at 11:35 am EDT
- 2021 Cantor Virtual Global Healthcare Conference – live fireside chat on Tuesday, September 28th at 2:40 pm EDT
Chinook will also participate in 1x1 meetings through Oppenheimer and Cantor Fitzgerald.
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
What conferences will Chinook Therapeutics participate in September 2021?
What is Chinook Therapeutics' lead program?
When can investors access the webcasts from Chinook Therapeutics' conferences?
What is the stock symbol for Chinook Therapeutics?
What kind of therapies does Chinook Therapeutics focus on?
